Stakeholders Seek Clarification of FDA’s Adolescent Oncology Patient Guidance

International Pharmaceutical Regulatory Monitor
A A
The FDA’s draft guidance on inclusion of adolescents in adult oncology clinical trials should clarify how the agency’s thinking aligns with international regulations, stakeholders said in comments on the June 1 draft.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00